Recruitment is ongoing for phase 1/1b trial proposing the use of ATR inhibitor BAY1895344 in combination with FOLFIRI chemotherapy in gastrointestinal cancer (including CRC) patients (NCTO4535401). This evidence concerns the gene ATR and colorectal carcinoma.